INCY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Incyte Corp (INCY) is a good buy for a beginner investor with a long-term investment strategy and $50,000-$100,000 available. The company's strong financial performance, positive news catalysts, and favorable analyst ratings outweigh the neutral technical indicators and lack of immediate trading signals.
The technical indicators are mixed. The MACD is negatively expanding, indicating bearish momentum, while the RSI is neutral at 29.77. Moving averages are converging, suggesting no clear trend. Key support is at 96.993, and resistance is at 99.704. The stock is trading near support levels, which could present a buying opportunity.
Positive opinion from the European Medicines Agency for Olumiant's use in treating severe alopecia areata in adolescents.
Strong Q4 2025 financial performance with 27.84% YoY revenue growth and 48.74% YoY net income growth.
Multiple analysts have raised their price targets recently, with several maintaining Buy or Overweight ratings.
Neutral sentiment from hedge funds and insiders, with no significant trading trends.
Concerns about Jakafi's loss of exclusivity, though analysts believe these fears are overestimated.
Downgrade by Wells Fargo citing limited near-term catalysts.
In Q4 2025, Incyte reported a 27.84% YoY increase in revenue to $1.51 billion, a 48.74% YoY increase in net income to $299.28 million, and a 50.52% YoY increase in EPS to $1.46. However, gross margin slightly declined to 91.96%, down 0.57% YoY.
Analyst sentiment is generally positive. Recent upgrades include price targets of $117 (Barclays), $120 (Stifel), and $110 (Piper Sandler), with Buy or Overweight ratings. However, Wells Fargo downgraded the stock to Equal Weight with a $107 price target, citing limited short-term catalysts.
